Tumor cells are depending on a useful ubiquitin-proteasome program, making it a lovely goal for the development of cancer therapeutics. Prescription drugs that inhibit the DUB exercise with the 19S proteasome can likely be applied as 2nd line therapy for individuals that do not respond to standard proteasome inhibitors. From https://jeffd085tzd9.wikilentillas.com/user